Connection

Özlem Türeci to Antineoplastic Agents, Immunological

Back to Details
This is a "connection" page, showing publications Özlem Türeci has written about Antineoplastic Agents, Immunological.
Özlem Türeci
Connection Strength
0.431
Antineoplastic Agents, Immunological
  1. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer. 2018 09; 100:17-26.
    View in: PubMed
    Score: 0.431
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.